Numerous preclinical and clinical evidence suggested that aberrant FGF21 signaling may play a role in the pathogenesis and progression of NAFLD (Liu et al., 2015; Rusli et al., 2016; Tucker et al., 2019). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.